Over the past five years, a wave of academic research has emerged which supports the notion that psychedelic-inspired medicines are effective and often superior treatments for things like addiction, ADHD, depression and anorexia.
Oregon voters last week approved a ballot initiative legalizing use of psilocybin — the psychedelic component of “magic” mushrooms — in a therapeutic setting.
Although some western US cities, including Denver, Oakland and Santa Cruz, had effectively removed threat of arrest or prosecution for possession of mushrooms last year, Oregon’s statewide vote could signal things to come in California, which could be the next state to relax laws outlawing possession of psilocybin mushrooms, ayahuasca, MDMA, and other psychedelic drugs.
Impressed with the latest improvements, State Sen. Scott Wiener (D-San Francisco) said Tuesday he plans to introduce legislation that would decriminalize psychedelics after the state Legislature reconvenes next month.
According to the National Institute of Mental Health, more than 17 million people in the U.S. and 300 million people worldwide have experienced major depression.
In a small study of adults with major depression, Johns Hopkins Medicine researchers report that two doses of the psychedelic substance psilocybin, given with supportive psychotherapy, produced rapid and large reductions in depressive symptoms, with most participants showing improvement and half of study participants achieving remission through the four-week follow-up.
The antidepressant effect of the psilocybin—the active compound in so-called magic mushrooms—was about four times greater than is typically seen in traditional antidepressants currently on the market.
Minerco, Inc. (OTC: MINE), is the world’s first publicly traded company specializing in growing, research, production and distribution of psilocybin mushrooms and marketing worldwide.
Last month, Minerco announced that the company is looking to open facility in Ann Arbor Michigan. MINE is now poised to take advantage of the Midwest market.
This is an exciting development for us to be one the the first companies to open a facility in the Midwest. Magic Mushrooms can heal so many people and provide a first mover advantage for our company ,” stated Julius Jenge, Chief Executive Officer of Minerco, Inc. Our commitment to research, production and distribution of psilocybin mushrooms, is now a reality, Minerco can be poised to help PSTD and work closer with Doctors in Ann Arbor. Michigan being the second largest medical Cannabis state in USA gives us an additional opportunity to thrive for our shareholders.